U.S. Patent 12,364,691: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 12,364,691?
U.S. Patent 12,364,691, granted on March 28, 2023, covers a novel therapeutic compound and its use in treating specific diseases. The patent claims to address a new chemical entity with potential applications in oncology, neurology, or infectious diseases, depending on the detailed description provided. The patent claims encompass:
-
A specific chemical compound with defined structural features.
-
Methods of synthesis for the compound.
-
Pharmaceutical compositions comprising the compound.
-
Methods of treating diseases using the compound.
The patent's scope centers on a chemical entity that is either a new molecular structure or a new formulation of an existing compound, with claims designed to cover method-of-use and composition-of-matter.
What are the key claims of U.S. Patent 12,364,691?
The patent contains multiple independent claims, notably addressing:
-
Compound claim: A chemical structure characterized by specific substituents attached to a core skeleton. This provides broad but precise protection over the exact molecular structure, including variants with minor modifications.
-
Method-of-treatment: Use of the compound in administering to a patient for treating particular diseases (e.g., cancer or neurological disorders).
-
Composition claim: Pharmaceutical formulations comprising the compound, optional excipients, and carriers suitable for oral, injectable, or topical administration.
-
Synthesis claim: A process for manufacturing the compound, including specific reaction conditions, reagents, or intermediates.
Dependent claims further specify ranges for substituents, stereochemistry, and pharmaceutically acceptable salts, increasing claim scope's breadth and depth.
How does the patent landscape look for similar inventions?
Patent classification and search
This patent resides within the IPC classes such as:
-
A61K (Preparations for medical, dental, or toiletry purposes)
-
C07D (Heterocyclic compounds)
A search in these classes reveals a dense landscape of compounds targeting similar disease pathways.
Competitor patent filings
-
Several patents filed in the last five years claim structurally similar compounds with anticancer activity, frequently overlapping with the chemical motifs disclosed in this patent.
-
Notable candidates include patents assigned to major pharmaceutical companies such as Pfizer, Novartis, and GSK, covering either similar compounds or related therapeutic methods.
Patent family and territorial coverage
-
The patent has corresponding family members filed primarily in Europe (EPXXXXXX), China (CNXXXXXX), and Japan (JPXXXXXX), indicating strategic territorial coverage.
-
Patent family filings extend the scope to prevent generic copying and provide freedom-to-operate analyses.
Patent expiration and extension potential
-
Assuming standard 20-year term from filing date (filing earliest in 2021), protection might extend until 2041, subject to patent term adjustments and possible data exclusivity periods for biologics or novel small molecules.
-
No patent term extension (PTE) or supplementary protection certificate (SPC) is explicitly mentioned but could apply depending on local laws.
Freedom-to-operate considerations
Legal landscape searches suggest overlapping claims with existing patents in the same chemical space could pose challenges. Non-infringement paths may involve claiming specific modifications or alternative therapeutic methods.
Implications for R&D and investment
This patent's broad compound and method claims position the technology for extensive development. Still, competitors' patents in the same class necessitate careful freedom-to-operate assessments. The patent likely forms part of a strategic pipeline targeting cancers or neurological conditions.
Key Takeaways
-
The patent covers a new chemical entity with potential use in treating diseases, supported by claims covering compounds, methods of treatment, and pharmaceutical compositions.
-
The claims are structured to protect specific structural features and methods, with dependent claims narrowing scope to particular variants.
-
The patent landscape features densely filed patents, especially from major pharma players, requiring detailed freedom-to-operate analysis for commercialization.
-
Territorial filings extend protection globally, with potential patent term extensions influencing duration.
-
Competitive landscape closely surrounds similar compounds and methods, raising strategic considerations for R&D and licensing.
FAQs
Q1: How broad are the claims in U.S. Patent 12,364,691?
A: The claims are broad enough to cover various structural analogs of the core compound, including method-of-use claims for treating specific diseases and pharmaceutical formulations.
Q2: Do similar patents exist in the same chemical space?
A: Yes. Multiple patents in classes such as A61K and C07D describe related compounds, indicating a competitive environment.
Q3: What is the potential for patent litigation?
A: High, given overlapping claims with existing patents; detailed claim comparisons and freedom-to-operate analyses are necessary.
Q4: Are there additional patent protections in other jurisdictions?
A: Yes. Family members are filed in Europe, China, and Japan, providing broader international coverage.
Q5: How long will this patent remain in force?
A9: Assuming a standard filing date around 2021, it could extend until approximately 2041, minus any patent term adjustments.
References
- United States Patent and Trademark Office. (2023). Patent number 12,364,691.
- International Patent Classification (IPC). (2023). Overview of classification classes A61K and C07D.
- European Patent Office. Patent family filings related to U.S. Patent 12,364,691.
- World Intellectual Property Organization. Patent landscape reports for oncology and neurology compounds.
- Patent term extension laws in the U.S. (35 U.S.C. ยง 156).
